European Innovation Council

BOYDSense is a medical device company founded in 2015 and headquartered in South San Francisco, California. The company specializes in developing non-invasive and affordable tools for measuring critical biomarkers through exhaled breath. BOYDSense focuses on breath-based metabolomics, which involves capturing, identifying, and quantifying volatile organic compound (VOC) biomarker patterns found in human breath. This innovative approach enables medical professionals to simplify the monitoring, screening, and risk stratification of chronic diseases, facilitating more effective diagnosis and ongoing management of these conditions.

NETRIS Pharma S.A.S. is a biotechnology company based in Lyon, France, focused on the identification and development of therapeutic molecules aimed at treating various forms of cancer. Established in 2008, the company specializes in targeting dependence receptors, which are trans-membrane proteins that play a crucial role in cellular signaling and tumor control. NETRIS Pharma conducts both in vitro and in vivo research, as well as preclinical practices, to manufacture drugs specifically for the treatment of breast cancer, lung cancer, glioblastoma, and neuroblastoma. Through its innovative approach, the company aims to advance cancer therapies and contribute to improved patient outcomes in the pharmaceutical industry.

Neuro Event Labs Oy, established in 2015 and headquartered in Tampere, Finland, specializes in developing artificial intelligence-based software for epilepsy patient monitoring. Their primary product collects accurate seizure data from patients at home and in hospitals, which is then analyzed and relayed to physicians for informed treatment decisions. This solution was developed in close collaboration with leading Finnish hospitals.

Cellbox Solutions is a technology company that specializes in innovative logistic solutions for the global BioMed industry. It has developed a carbon dioxide incubator designed for the storage, isolation, handling, and analysis of biological materials. This incubator offers essential logistic services and ensures the proper handling of living cells, facilitating their storage, reproduction, transportation, and analysis. By enabling the transportation of living cells via various methods, including road, rail, and air, Cellbox Solutions supports healthcare providers in their efforts to deliver the latest therapies to patients.

InProTher Aps is a biotechnology company based in Copenhagen, Denmark, focusing on the development of innovative vaccine technologies and candidates within the field of immunotherapy. Established in 2011, the company is dedicated to creating the first adaptive immune therapy that targets immunosuppressive genes associated with ancient retroviruses. InProTher is also engaged in the development of products aimed at combating HIV, papilloma viruses, and various forms of cancer. Through its research and development efforts, InProTher seeks to advance treatment options in the evolving landscape of immunotherapy.

GrayMatters Health develops digital therapeutics for mental health and related neurological disorders, grounded in self-regulation of brain processes and brain biomarkers. The technology aims to deliver self-neuromodulation treatments that enhance efficacy, safety, and accessibility, enabling healthcare professionals to use neuroscience-based digital interventions within clinical practice and to complement conventional care with non-pharmacological options.

Brainhero offers home-based neurofeedback therapy using EEG technology. It aims to help children manage symptoms of Autism Spectrum Disorder (ASD) and Attention Deficit Hyperactivity Disorder (ADHD) through engaging, app-based brain training.

ALA Diagnostics specializes in the development and marketing of in vitro diagnostic kits aimed at addressing prevalent pathologies and unresolved medical needs. The company focuses on creating diagnostic solutions, including kits specifically designed for the early diagnosis of multiple sclerosis. These kits are engineered for seamless integration into the clinical routines of hospitals and medical centers, allowing healthcare professionals to deliver accurate results efficiently. By improving diagnostic capabilities, ALA Diagnostics contributes to enhancing the quality of life for individuals affected by multiple sclerosis and potentially other conditions, leveraging synergies with public organizations renowned for their innovative project initiatives.

Lattice Medical is a French medical device company focused on breast reconstruction after cancer. It designs and manufactures implantable devices that promote regeneration of autologous adipose tissue to enable natural breast reconstruction following mastectomy. The flagship implant, MATTISSE, uses 3D printing and fully biodegradable materials to provide personalized reconstruction in a single surgery, reducing operative time and invasiveness. The company aims to offer an alternative to silicone-based implants by supporting tissue regeneration rather than replacement. Founded in 2017 and based in Loos, France, Lattice Medical develops solutions to address clinical and societal needs by restoring form and function for women recovering from breast cancer.

Celeris Therapeutics is an AI-first drug discovery company that focuses on developing proximity-inducing compounds (PICs), particularly PIC degraders, to address high unmet medical needs in diseases like Parkinson's and various cancers. The company has created the Celeris One platform, which utilizes structure-based geometric deep learning to enhance the design and development of degraders by prioritizing specific E3 ligases, designing effective linkers, and selecting optimal compounds for synthesis. Additionally, Celeris Therapeutics operates an in-house automated laboratory that facilitates rapid generation of experimental data for further optimization. The company collaborates with pharmaceutical and biotech firms to discover and develop small-molecule degrader therapies across multiple therapeutic areas, while also advancing its own internal drug pipeline. Celeris Therapeutics maintains offices in Menlo Park, California, and Graz, Austria.

Celeris Therapeutics is an AI-first drug discovery company that focuses on developing proximity-inducing compounds (PICs), particularly PIC degraders, to address high unmet medical needs in diseases like Parkinson's and various cancers. The company has created the Celeris One platform, which utilizes structure-based geometric deep learning to enhance the design and development of degraders by prioritizing specific E3 ligases, designing effective linkers, and selecting optimal compounds for synthesis. Additionally, Celeris Therapeutics operates an in-house automated laboratory that facilitates rapid generation of experimental data for further optimization. The company collaborates with pharmaceutical and biotech firms to discover and develop small-molecule degrader therapies across multiple therapeutic areas, while also advancing its own internal drug pipeline. Celeris Therapeutics maintains offices in Menlo Park, California, and Graz, Austria.

AuriGen Medical Limited is an innovative company based in Dublin, Ireland, specializing in electrophysiology and structural heart solutions. Founded in 2016, AuriGen develops advanced left atrial appendage (LAA) implants aimed at addressing the stroke and arrhythmia risks associated with persistent atrial fibrillation (AF). The company targets a significant and growing patient population, particularly those with medication-resistant AF, which affects over three million individuals across the United States and Europe. AuriGen's technology offers a novel trans-septal implant that not only treats AF effectively but also reduces the reliance on anticoagulants and anti-arrhythmic medications. By providing cost-effective treatment options, AuriGen aims to improve patient outcomes while addressing the rising financial burden of managing chronic cardiac conditions in aging populations.

PhosPrint, established in 2019 and headquartered in Agia Paraskevi, Attiki, specializes in laser bioprinting systems and regenerative medicine. The company's core business involves developing and providing on-site cell printing during surgeries, aiming to facilitate tissue regeneration and advance medical research. PhosPrint's offerings include healthcare technology products that leverage laser bioprinting and biotechnology research, enabling researchers and medical professionals to access innovative tools and procedures to combat diseases and medical conditions.

Betalin Therapeutics is a privately-held company dedicated to developing innovative cell therapy solutions for insulin-dependent diabetes through its Engineered Micro-Pancreas (EMP) technology. This platform combines harvested pancreatic islets, known as Islets of Langerhans, with a proprietary biological micro-environment designed to support these cells. The EMP aims to offer an alternative to traditional insulin therapy, potentially eliminating the need for insulin injections and glucose monitoring in patients. Following promising in-vitro and preliminary in-vivo results, Betalin Therapeutics is focused on optimizing the therapy using animal models and preparing to submit an Investigational New Drug (IND) application to the FDA in anticipation of advancing to clinical trials.

Cardiac Success develops medical devices aimed at improving cardiac function in patients with heart failure and related conditions. The company is behind implants intended to enhance cardiac output in those with heart failure and functional mitral regurgitation, and it has developed the V-sling, a transcatheter ventricular repair device based on a surgical papillary muscle approximation technique, designed to aid patients with heart failure with reduced ejection fraction.

GrayMatters Health develops digital therapeutics for mental health and related neurological disorders, grounded in self-regulation of brain processes and brain biomarkers. The technology aims to deliver self-neuromodulation treatments that enhance efficacy, safety, and accessibility, enabling healthcare professionals to use neuroscience-based digital interventions within clinical practice and to complement conventional care with non-pharmacological options.

BOYDSense is a medical device company founded in 2015 and headquartered in South San Francisco, California. The company specializes in developing non-invasive and affordable tools for measuring critical biomarkers through exhaled breath. BOYDSense focuses on breath-based metabolomics, which involves capturing, identifying, and quantifying volatile organic compound (VOC) biomarker patterns found in human breath. This innovative approach enables medical professionals to simplify the monitoring, screening, and risk stratification of chronic diseases, facilitating more effective diagnosis and ongoing management of these conditions.

Askel is a medical technology company specializing in knee cartilage repair. Its innovative device aims to enhance recovery, prevent osteoarthritis, reduce healthcare costs, and facilitate swift rehabilitation.

InProTher Aps is a biotechnology company based in Copenhagen, Denmark, focusing on the development of innovative vaccine technologies and candidates within the field of immunotherapy. Established in 2011, the company is dedicated to creating the first adaptive immune therapy that targets immunosuppressive genes associated with ancient retroviruses. InProTher is also engaged in the development of products aimed at combating HIV, papilloma viruses, and various forms of cancer. Through its research and development efforts, InProTher seeks to advance treatment options in the evolving landscape of immunotherapy.

Op2Lysis is a biotechnology company focused on developing innovative treatments for hemorrhagic stroke. The company specializes in a thrombolytic drug designed to dissolve intracerebral hematomas, which are blood clots that can lead to significant disability if not addressed. This drug utilizes vectorization technology and is intended to be administered locally through a catheter, allowing for micro-invasive surgical procedures. By effectively liquefying the hematoma, Op2Lysis aims to provide patients with a safer alternative to major surgeries, thereby improving recovery outcomes and reducing long-term disabilities associated with hemorrhagic strokes.

NETRIS Pharma S.A.S. is a biotechnology company based in Lyon, France, focused on the identification and development of therapeutic molecules aimed at treating various forms of cancer. Established in 2008, the company specializes in targeting dependence receptors, which are trans-membrane proteins that play a crucial role in cellular signaling and tumor control. NETRIS Pharma conducts both in vitro and in vivo research, as well as preclinical practices, to manufacture drugs specifically for the treatment of breast cancer, lung cancer, glioblastoma, and neuroblastoma. Through its innovative approach, the company aims to advance cancer therapies and contribute to improved patient outcomes in the pharmaceutical industry.

NETRIS Pharma S.A.S. is a biotechnology company based in Lyon, France, focused on the identification and development of therapeutic molecules aimed at treating various forms of cancer. Established in 2008, the company specializes in targeting dependence receptors, which are trans-membrane proteins that play a crucial role in cellular signaling and tumor control. NETRIS Pharma conducts both in vitro and in vivo research, as well as preclinical practices, to manufacture drugs specifically for the treatment of breast cancer, lung cancer, glioblastoma, and neuroblastoma. Through its innovative approach, the company aims to advance cancer therapies and contribute to improved patient outcomes in the pharmaceutical industry.

Op2Lysis is a biotechnology company focused on developing innovative treatments for hemorrhagic stroke. The company specializes in a thrombolytic drug designed to dissolve intracerebral hematomas, which are blood clots that can lead to significant disability if not addressed. This drug utilizes vectorization technology and is intended to be administered locally through a catheter, allowing for micro-invasive surgical procedures. By effectively liquefying the hematoma, Op2Lysis aims to provide patients with a safer alternative to major surgeries, thereby improving recovery outcomes and reducing long-term disabilities associated with hemorrhagic strokes.

Fibriant is a biotechnology company specializing in the development and production of recombinant fibrinogen, a protein crucial for blood clotting, tissue repair, and infection defense.

Cardiac Success develops medical devices aimed at improving cardiac function in patients with heart failure and related conditions. The company is behind implants intended to enhance cardiac output in those with heart failure and functional mitral regurgitation, and it has developed the V-sling, a transcatheter ventricular repair device based on a surgical papillary muscle approximation technique, designed to aid patients with heart failure with reduced ejection fraction.

Fibriant is a biotechnology company specializing in the development and production of recombinant fibrinogen, a protein crucial for blood clotting, tissue repair, and infection defense.

GrayMatters Health develops digital therapeutics for mental health and related neurological disorders, grounded in self-regulation of brain processes and brain biomarkers. The technology aims to deliver self-neuromodulation treatments that enhance efficacy, safety, and accessibility, enabling healthcare professionals to use neuroscience-based digital interventions within clinical practice and to complement conventional care with non-pharmacological options.

Lattice Medical is a French medical device company focused on breast reconstruction after cancer. It designs and manufactures implantable devices that promote regeneration of autologous adipose tissue to enable natural breast reconstruction following mastectomy. The flagship implant, MATTISSE, uses 3D printing and fully biodegradable materials to provide personalized reconstruction in a single surgery, reducing operative time and invasiveness. The company aims to offer an alternative to silicone-based implants by supporting tissue regeneration rather than replacement. Founded in 2017 and based in Loos, France, Lattice Medical develops solutions to address clinical and societal needs by restoring form and function for women recovering from breast cancer.

PROSION Therapeutics is a biotechnology company developing innovative drugs to address previously undruggable targets linked to various hard-to-treat diseases, including cancer, diabetes, Alzheimer's, and cardiovascular diseases.

InProTher Aps is a biotechnology company based in Copenhagen, Denmark, focusing on the development of innovative vaccine technologies and candidates within the field of immunotherapy. Established in 2011, the company is dedicated to creating the first adaptive immune therapy that targets immunosuppressive genes associated with ancient retroviruses. InProTher is also engaged in the development of products aimed at combating HIV, papilloma viruses, and various forms of cancer. Through its research and development efforts, InProTher seeks to advance treatment options in the evolving landscape of immunotherapy.

HIL Applied Medical is developing a new class of ultra-compact, high-performance accelerators for proton therapy. The company applies a patented approach to particle acceleration and beam delivery, combining nano-technology with ultra-high-intensity lasers and ultra-fast magnets. These advances aim to reduce the size, complexity and cost of proton therapy systems while preserving clinical utility, with the goal of a single-room add-on solution that is truly cost-effective. HIL Applied Medical is a privately held company backed by venture investors and global strategic partners. It is headquartered in the High-Tech Park in Givat Ram, Jerusalem, Israel, and maintains a wholly owned subsidiary in Reno, Nevada.

Quantib develops radiology software that employs machine learning techniques to analyze MRI and CT scans. Its platform automates segmentation, classification, quantification, and visualization tasks, accelerating diagnostic workflows for physicians and researchers.

Neuro Event Labs Oy, established in 2015 and headquartered in Tampere, Finland, specializes in developing artificial intelligence-based software for epilepsy patient monitoring. Their primary product collects accurate seizure data from patients at home and in hospitals, which is then analyzed and relayed to physicians for informed treatment decisions. This solution was developed in close collaboration with leading Finnish hospitals.

Betalin Therapeutics is a privately-held company dedicated to developing innovative cell therapy solutions for insulin-dependent diabetes through its Engineered Micro-Pancreas (EMP) technology. This platform combines harvested pancreatic islets, known as Islets of Langerhans, with a proprietary biological micro-environment designed to support these cells. The EMP aims to offer an alternative to traditional insulin therapy, potentially eliminating the need for insulin injections and glucose monitoring in patients. Following promising in-vitro and preliminary in-vivo results, Betalin Therapeutics is focused on optimizing the therapy using animal models and preparing to submit an Investigational New Drug (IND) application to the FDA in anticipation of advancing to clinical trials.

Neuro Event Labs Oy, established in 2015 and headquartered in Tampere, Finland, specializes in developing artificial intelligence-based software for epilepsy patient monitoring. Their primary product collects accurate seizure data from patients at home and in hospitals, which is then analyzed and relayed to physicians for informed treatment decisions. This solution was developed in close collaboration with leading Finnish hospitals.

Betalin Therapeutics is a privately-held company dedicated to developing innovative cell therapy solutions for insulin-dependent diabetes through its Engineered Micro-Pancreas (EMP) technology. This platform combines harvested pancreatic islets, known as Islets of Langerhans, with a proprietary biological micro-environment designed to support these cells. The EMP aims to offer an alternative to traditional insulin therapy, potentially eliminating the need for insulin injections and glucose monitoring in patients. Following promising in-vitro and preliminary in-vivo results, Betalin Therapeutics is focused on optimizing the therapy using animal models and preparing to submit an Investigational New Drug (IND) application to the FDA in anticipation of advancing to clinical trials.

moveUP develops digital therapeutics solutions, focusing on improving patient engagement and streamlining healthcare delivery. Its closed-loop system ensures high compliance and better outcomes by continuously collecting data to personalize treatment. Currently, it offers a therapy for orthopaedic patients undergoing joint surgery, with CE medical device certification.

moveUP develops digital therapeutics solutions, focusing on improving patient engagement and streamlining healthcare delivery. Its closed-loop system ensures high compliance and better outcomes by continuously collecting data to personalize treatment. Currently, it offers a therapy for orthopaedic patients undergoing joint surgery, with CE medical device certification.

Founded in Finland in 2011, Desentum is a biopharmaceutical company dedicated to developing innovative allergy vaccines. Its unique approach involves designing vaccines that switch the immune system's response from hypersensitivity to tolerance, aiming to provide long-term relief for patients suffering from allergies.